A study done to find out how well triamcinolone acetonide, pentoxifylline, and the two of them together help in growing hair back after being injected into areas where alopecia areata has caused hair loss.

A clinico- dermoscopic study of comparison of intralesional triamcinolone acetonide, pentoxifylline and their combination in treatment of alopecia areata - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/03/064833

Enrollment

Registered

2024-03-27

Start date

Unknown

Completion date

Unknown

Last updated

2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L639- Alopecia areata, unspecified

Interventions

Intervention1: Intralesional injection of pentoxifylline: 0.1 mL pentoxifylline (20 mg per mL concentration) injected intralesionally into patch using a insulin syringe (0.5 inch long syringe with 30

Eligibility

Inclusion criteria

Inclusion criteria: Clinically and dermoscopically diagnosed patients with single or multiple patches of alopecia areata

Exclusion criteria

Exclusion criteria: 1. Non-consenting patients 2. Patients with alopecia affecting more than 50% of scalp 3. Any treatment taken for alopecia in the past one month. 4. Prior history of allergic reactions to pentoxifylline, triamcinolone, or injection adjuvants or components 5. Pregnant and lactating females 6. Localised infection at injection site. 7. Known case of HIV, Hepatitis B and Hepatitis C or any other immune-compromised disease 8. Patient on systemic steroids or any other immunosuppressive treatment. 9. Acute febrile or any other bacterial infection. 10. Asthma, allergic skin disorder, history of convulsions 11. Bleeding disorders.

Design outcomes

Primary

Measure	Time frame
Hair regrowth in alopecia patches measured using 5-point semi-quantitative score regrowth scale (RGS) and dermoscopically.Timepoint: Monthly assessment till 6 months after last injection	—

Secondary

Measure	Time frame
Dermoscopic changes of alopecia areata during treatmentTimepoint: Monthly assessment till 6 months after last injection	—

Countries

India

Contacts

Public ContactVinayak Viswanath

St. Johns Medical College Hospital

vinayak.viswanath@StJohns.in9400726787

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026